<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Liver Neoplasms</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

      <h1>Liver Neoplasms</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
        <!-- READ SUMMARY CONTAINER -->
        
              <!-- Summary Overlay -->
              <div class="summary-overlay" id="summaryOverlay"></div>
        
        
              <div class="summary-card" id="summaryCard">
                
                <div class="summary-header">
                  <h3>Note Summary</h3>
                  <div class="icon-box">
                    <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                    <img src="../images/icons/summary.png" alt="Icon" class="icon">
                  </div>
                </div>
                <div class="summary-content">
                  <!-- Summary content goes here -->
                  <p><i>This content is not available yet.</i></p>
        
                  <span class="close-btn" id="closeBtn">close</span>
                </div>
              </div>
        
              <div class="summary-trigger" id="summaryTrigger">
                <p>Click here to read a summary</p>
            </div>
        <!-- END OF READ SUMMARY CONTAINER -->
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Benign Liver Tumors and Tumor-like Conditions</a>
          </h2>
        </header>
        <div class='body'>

            <ul>
              <li><strong>Hepatocellular origin:</strong></li>
              <ul>
                <li><strong>Hepatocellular adenoma</strong></li>
                <li><strong>Hepatocellular hyperplasia:</strong></li>
                <ul>
                  <li><strong>Focal nodular hyperplasia</strong></li>
                  <li><strong>Nodular regenerative hyperplasia</strong></li>
                  <li><strong>Macroregenerative nodule</strong></li>
                  <li><strong>Dysplastic nodules</strong></li>
                </ul>
              </ul>
              <li><strong>Cholangiocellular origin:</strong></li>
              <ul>
                <li><strong>Hepatic cysts:</strong></li>
                <ul>
                  <li><strong>Simple hepatic cysts</strong></li>
                  <li><strong>Polycystic liver disease</strong></li>
                </ul>
                <li><strong>Biliary hamartoma</strong></li>
                <li><strong>Biliary cystadenoma</strong></li>
                <li><strong>Bile duct adenoma</strong></li>
              </ul>
              <li><strong>Mesenchymal origin:</strong></li>
              <ul>
                <li><strong>Mesenchymal hamartoma</strong></li>
                <li><strong>Hemangioma</strong></li>
                <li><strong>Infantile hemangioendothelioma</strong></li>
                <li><strong>Lymphangioma</strong></li>
                <li><strong>Lipoma/Angiomyolipoma/myelolipoma</strong></li>
                <li><strong>Leiomyoma</strong></li>
                <li><strong>Fibroma</strong></li>
              </ul>
              <li><strong>Heterotopic tissue:</strong> Adrenal rests/Pancreatic rests</li>
            </ul>
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Classification</a>
          </h2>
        </header>
        <div class='body'>

          <br>
            <table class="note-table">
              <tr>
                <th>Benign</th>
                <th>Malignant</th>
              </tr>
              <tr>
                <td>
                  <ul>
                    <li><strong>Haemangioma</strong></li>
                    <li> Focal nodular hyperplasia</li>
                    <li>Adenoma</li>
                    <li>Liver cysts</li>
                    <li>Nodular regenerative hyperplasia</li>
                  </ul>                  
                </td>


                <td>
                    <ol>
                       <li><strong>Primary liver cancers</strong></li> 
                        <ul>
                            <li>Hepatocellular carcinoma</li>
                            <li>Fibrolamellar carcinoma</li>
                            <li>Hepatoblastoma</li>
                        </ul>
                        <li>Metastases</li>
                    </ol>
                
                </td>
              </tr>

            </table>
            





        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Benign Liver Tumours (BLT)</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li><strong>BLT</strong> are extremely frequent, varied, and mostly asymptomatic.</li>
            <li>Each cellular component of the liver (e.g., hepatocyte, biliary, endothelial, or other mesenchymal cells) can undergo benign proliferation.</li>
            <li>Only four lesions have common clinical relevance.</li>
          </ul>
          
          <h4>Benign Liver Lesions</h4>
          <ol>
            <li><strong>Haemangioma</strong></li>
            <li><strong>Focal nodular hyperplasia</strong></li>
            <li><strong>Adenoma</strong></li>
            <li><strong>Cysts</strong></li>
          </ol>
          
          <section id='heading-3-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-1'>Haemangioma</a>
              </h3>
            </header>
            <div class='body'>
              <h4>Clinical Features</h4>
              <ul>
                <li>The most common benign primary liver tumor.</li>
                <li>Occurrence in the general population ranges from <strong>0.4-20%</strong>.</li>
                <li>Arises from endothelial cells that line blood vessels.</li>
                <li>Usually single and small.</li>
                <li>Well-demarcated capsule.</li>
                <li>Usually asymptomatic.</li>
                <li><strong>RUQ pain</strong>, <strong>early satiety</strong>, and signs of <strong>portal hypertension</strong> may occur with giant haemangiomas.</li>
                <li>Small lesions do not require follow-up imaging or treatment.</li>
              </ul>
              
              <h4>Diagnosis</h4>
              <ul>
                <li><strong>USS:</strong> echogenic spot, well demarcated.</li>
                <li><strong>CT scan:</strong> venous enhancement from periphery to center.</li>
                <li><strong>MRI:</strong> high-intensity area.</li>
                <li>No need for <strong>fine needle aspiration for cytology (FNAC)</strong>.</li>
                <li>The best diagnostic tests for detection include contrast-enhanced CT scan or MRI.</li>
              </ul>
              <h4>Treatment</h4>
              <ul>
                <li>No need for treatment.</li>
                <li>Surgical resection for large tumor with associated symptoms.</li>
              </ul>

                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/liver-neoplasms (2).jpg" alt="" onclick="openModal(this)">
              <div class="caption">Ultrasound Image of Hemangioma</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">Ultrasound Image of Hemangioma</div>
            </div>

                        <!-- image here -->
            <div class="image-container">
                <img src="../figures/liver-neoplasms (3).jpg" alt="" onclick="openModal(this)">
                <div class="caption">MRI of Hemangioma</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">MRI of Hemangioma</div>
              </div>
            </div>
          </section>

          <section id='heading-3-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-2'>Focal Nodular Hyperplasia (FNH)</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>The second most common form of BLT.</li>
                <li>Benign nodule formation of normal liver tissue.</li>
                <li>Central stellate scar.</li>
                <li>More common in young women between the ages of <strong>20 and 30 years</strong>.</li>
                <li>No relationship with sex hormones.</li>
                <li>Usually asymptomatic and don‚Äôt require treatment.</li>
                <li>May cause minimal pain.</li>
              </ul>
              
              <h4>Diagnosis:</h4>
              <ul>
                <li><strong>USS:</strong> Nodule with varying echogenicity.</li>
                <li><strong>CT:</strong> Hypervascular mass with central scar.</li>
                <li><strong>MRI:</strong> Iso or hypo intense lesion.</li>
                <li><strong>FNAC:</strong> Normal hepatocytes and Kupffer cells with central core.</li>
              </ul>
              <h4>Treatment:</h4>
              <ul>
                <li>No treatment necessary.</li>
                <li>If they are large, surgical removal is recommended to prevent the risk of rupture (but this is uncommon).</li>
              </ul>
              
            </div>
          </section>


          <section id='heading-3-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-3'>Hepatic Adenoma</a>
              </h3>
            </header>
            <div class='body'>
              <h4>Clinical Features</h4>
              <ul>
                <li>Are uncommon benign epithelial liver tumors in an otherwise normal-appearing liver.</li>
                <li>Composed of normal hepatocytes, no portal tract, central veins, or bile ducts.</li>
                <li>More common in women (20-44 years).</li>
                <li>Usually in the right lobe, typically solitary (70-80%).</li>
                <li>May be multiple in prolonged contraceptive use, glycogen storage diseases, and hepatic adenomatosis.</li>
                <li>Associated with oral contraceptive use.</li>
                <li>Usually asymptomatic but may have right upper quadrant (RUQ) pain.</li>
                <li>May present with rupture, haemorrhage, or malignant transformation (very rare).</li>
              </ul>
              

              <h5>Diagnosis</h5>
              <ul>
                <li><strong>USS:</strong> Filling defect.</li>
                <li><h4strong>CT:</strong> Diffuse arterial enhancement.</li>
                <li><strong>MRI:</strong> Hypo or hyper intense lesion.</li>
                <li><strong>FNAC:</strong> May be needed.</li>
              </ul>
              <h5>Treatment</h5>
              <ul>
                <li>Stop hormones or OCPs.</li>
                <li>Observe every 6 months for 2 years.</li>
                <li>If no regression then surgical excision.</li>
              </ul>
              
            </div>
          </section>


          <section id='heading-3-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-4'>Nodular Regenerative Hyperplasia</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>A rare parenchymatous liver disease.</li>
                <li>Characterized by diffuse benign transformation of the hepatic parenchyma into multiple small nodules (composed of regenerating hepatocytes).</li>
                <li>Usually asymptomatic but can lead to the development of non-cirrhotic portal hypertension and its complications - oesophageal variceal bleeding, hypersplenism, and ascites.</li>
                <li>Often associated with rheumatologic, autoimmune, hematologic, myeloproliferative disorders, immune deficiency states, and exposure to certain drugs and toxins.</li>
                <li>Diagnosis is made by liver biopsy and may require an open or laparoscopic biopsy since nodules can be missed.</li>
              </ul>
              

            </div>
          </section>


          <section id='heading-3-5'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-5'>Liver Cysts</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>May be single or multiple.</li>
                <li>Polycystic liver disease is a hereditary condition that may be part of autosomal dominant polycystic kidney disease or may result from a different genetic mutation that leads solely to autosomal dominant polycystic liver disease.</li>
                <li>Patients are often asymptomatic.</li>
                <li>No specific management required.</li>
                <li><strong>Hydatid cyst</strong>.</li>
              </ul>
              
              <section id='heading-3-5-1'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-5-1'>Simple Cysts</a>
                  </h4>
                </header>
                <div class='body'>
                  <ul>
                    <li>Simple hepatic cysts are one of the commonest liver lesions, occurring in <strong>2-7%</strong> of the population.</li>
                    <li>Are solitary more than <strong>50%</strong> of the time and asymptomatic more than <strong>90%</strong> of the time.</li>
                    <li>There may be a slight female predilection.</li>
                    <li>Usually incidental findings.</li>
                    <li>Size can range up to <strong>20 cm</strong>, although most are less than <strong>5 cm</strong>.</li>
                    <li>Asymptomatic simple cysts require no intervention but should be observed.</li>
                    <li>The symptoms are usually related to mass effect, causing pain in the right upper quadrant and occasionally early satiety.</li>
                    <li>Nausea, vomiting, and abdominal distension may also be present.</li>
                    <li>Rarely, intra-cystic hemorrhage and infection may develop.</li>
                    <li>Treatment options for symptomatic cysts include: aspiration with or without sclerosants, laparoscopic unroofing, cystojejunostomy, and resection.</li>
                  </ul>
                  
                    <!-- image here -->
                    <div class="image-container">
                      <img src="../figures/liver-neoplasms (4).jpg" alt="" onclick="openModal(this)">
                      <div class="caption">Simple cysts MRI</div>
                    </div>
                    
                    <div id="myModal" class="modal">
                      <span class="close" onclick="closeModal()">&times;</span>
                      <img class="modal-content" id="modalImage">
                      <div id="caption" class="caption">Simple cysts MRI</div>
                    </div>

                    <h4>Liver Cysts</h4>
                    <ul>
                      <li>If multiple simple cysts are seen, consider polycystic liver disease.</li>
                      <li>This is an inherited condition (autosomal dominant), often found in association with renal cysts.</li>
                      <li>The majority of patients with polycystic liver disease remain asymptomatic with preserved liver function and do not require surgical intervention.</li>
                      <li>Fenestration is a technique that combines aspiration with surgical deroofing of a cyst in a single procedure.</li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-3-5-2'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-5-2'>Complex Cysts</a>
                  </h4>
                </header>
                <div class='body'>
                  <ul>
                    <li>Radiologically, internal septations are almost always seen in cystadenomas on contrast-enhanced CT or MRI.</li>
                    <li>A biliary cystadenoma is an uncommon benign cystic neoplasm of the liver.</li>
                    <li>Occur predominantly in middle-aged patients and are more common in women.</li>
                    <li>Cystadenomas have irregular borders and a thick stromal layer, and calcifications and mural nodules can occasionally be seen in the walls.</li>
                    <li>Variable clinical presentation depending on size and location of the cyst.</li>
                    <li>Symptoms may include RUQ pain, obstructive jaundice, palpable liver edge or mass, increasing abdominal girth (large tumors), nausea, vomiting.</li>
                    <li>There is no association with OCPs.</li>
                    <li>Best treatment is surgical resection as <strong>15%</strong> of tumors undergo malignant transformation.</li>
                  </ul>
                  
        
                              <!-- image here -->
            <div class="image-container">
              <img src="../figures/liver-neoplasms (5).jpg" alt="" onclick="openModal(this)">
              <div class="caption">Complex cysts MRI</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">Complex cysts MRI</div>
            </div>
                </div>
              </section>
            </div>
          </section>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Malignant Liver Tumors</a>
          </h2>
        </header>
        <div class='body'>
          <ol>
            <li><strong>Hepatocellular carcinoma (HCC)</strong></li>
            <li><strong>Fibrolamellar carcinoma of the liver</strong></li>
            <li><strong>Hepatoblastoma</strong></li>
            <li><strong>Intrahepatic cholangiocarcinoma</strong></li>
            <li><strong>Others - lymphoma</strong></li>
          </ol>
          
          <section id='heading-4-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-1'>Hepatocellular Carcinoma (HCC)</a>
              </h3>
            </header>
            <div class='body'>
              <h4>Incidence</h4>
              <ul>
                <li>The most common primary liver cancer.</li>
                <li>HCC is the 5th commonest cancer in the world but the 3rd commonest cause of cancer death.</li>
                <li>Worldwide, it is responsible for <strong>600,000 deaths</strong> annually.</li>
                <li>The average duration of illness in Nigeria from onset of symptoms to death is <strong>16.3 weeks</strong> (approximately 4 months).</li>
                <li>Screening is therefore recommended in high-risk persons for HCC.</li>
              </ul>
              
              <h4>Risk Factors</h4>
              <p>The most important risk factor is cirrhosis from any cause:</p>
              <ol>
                <li><strong>Hepatitis B</strong> (integrates in host DNA)</li>
                <li><strong>Hepatitis C</strong></li>
                <li>Significant alcohol consumption</li>
                <li>Non-alcoholic steatohepatitis</li>
                <li>Autoimmune hepatitis</li>
                <li>Genetic haemochromatosis</li>
                <li>Primary biliary cirrhosis</li>
                <li>Œ±1-antitrypsin deficiency</li>
                <li>Aflatoxin</li>
                <li>Positive family history of HCC</li>
              </ol>
              

              <h4>Clinical Features</h4>
              <ul>
                <li><strong>Weight loss and RUQ pain</strong> (most common).</li>
                <li>Abdominal swelling/mass.</li>
                <li>Asymptomatic in early disease.</li>
                <li>Worsening of pre-existing chronic liver disease.</li>
                <li>Acute liver failure.</li>
              </ul>
              <p>O/E:</p>
              <ul>
                <li>Signs of cirrhosis.</li>
                <li>Hard enlarged RUQ mass.</li>
                <li>Liver bruit.</li>
              </ul>
              
              <h4>Metastases</h4>
              <ul>
                <li>Rest of the liver</li>
                <li>Portal vein</li>
                <li>Lymph nodes</li>
                <li>Lungs</li>
                <li>Bone</li>
                <li>Brain</li>
              </ul>
              
              <h4>Systemic Features</h4>
              <ul>
                <li>Hypercalcemia</li>
                <li>Hypoglycemia</li>
                <li>Polycythemia</li>
              </ul>
              <h4>Laboratory Tests</h4>
              <ul>
                <li>Lab features of liver cirrhosis may be present.</li>
                <li>AFP (Alpha-fetoprotein)</li>
                <ul>
                  <li>Is a tumor marker for HCC.</li>
                  <li>Serum AFP value &gt;200ng/ml plus imaging evidence of focal hepatic lesion is highly specific for HCC diagnosis.</li>
                  <li>Elevation seen in more than 70% of patients.</li>
                </ul>
              </ul>

         
              <h4>Diagnosis</h4>
              <ul>
                <li>Clinical presentation</li>
                <li>Elevated AFP</li>
                <li>Abdominal USS</li>
                <li>Triple-phase helical CT scan</li>
                <li>Contrast-enhanced MRI</li>
                <li>The presence of arterial enhancement followed by washout has a sensitivity and specificity of 90% and 95%, respectively.</li>
                <li>Biopsy</li>
              </ul>
              <h4>Prognosis</h4>
              <ul>
                <li>Tumor size</li>
                <li>Extra-hepatic spread</li>
                <li>Underlying liver disease</li>
                <li>Patient performance status</li>
              </ul>
              

                          <!-- image here -->
            <div class="image-container">
              <img src="../figures/liver-neoplasms (6).jpg" alt="" onclick="openModal(this)">
              <div class="caption">BCLC Classification, Staging and Treatment</div>
            </div>
            
            <div id="myModal" class="modal">
              <span class="close" onclick="closeModal()">&times;</span>
              <img class="modal-content" id="modalImage">
              <div id="caption" class="caption">BCLC Classification, Staging and Treatment</div>
            </div>


            <section id='heading-4-1-1'>
              <header>
                <h4>
      
                  <a aria-hidden href='#heading-4-1-1'>Treatment Options for HCC</a>
                </h4>
              </header>
              <div class='body'>
                <ul>
                  <li><strong>Surgery</strong>
                    <ol>
                      <li>Hepatic resection</li>
                      <li>Liver transplantation</li>
                    </ol>
                  </li>
                  <li><strong>Loco-Regional Therapies</strong>
                    <ol>
                      <li>Percutaneous ethanol injection (PEI)</li>
                      <li>Radiofrequency ablation (RFA)</li>
                      <li>Microwave ablation</li>
                      <li>Cryoablation</li>
                      <li>High intensity focused ultrasound ablation</li>
                      <li>Transarterial chemoembolization (TACE)</li>
                    </ol>
                  </li>
                  <li><strong>Systemic chemotherapy</strong> (e.g., sorafenib) and radiotherapy</li>
                  <li><strong>Symptomatic treatment</strong></li>
                </ul>
                
    
                <h4>Hepatic Resection</h4>
                <ul>
                  <li>Feasible for small tumors with preserved liver function (no jaundice or portal hypertension).</li>
                  <li>The treatment of choice for HCC without background cirrhosis.</li>
                  <li>Only <strong>5%-15%</strong> of HCC patients are eligible (much less in Nigeria).</li>
                  <li>Survival rates: 1 year <strong>97%</strong>, 3 years <strong>84%</strong>, and 5 years <strong>26%-57%</strong>.</li>
                  <li>Factors affecting recurrence include: tumor size, number of tumors, vascular invasion, and width of resection margin.</li>
                </ul>
                
                <h4>Liver Transplantation</h4>
                <ul>
                  <li>Performed in patients with non-resectable tumor but confined to the liver or in those with background cirrhosis & poor liver function.</li>
                  <li>Only if single tumor ‚â§ 5cm or maximum of 3 tumors each &lt; 3 cm in diameter.</li>
                  <li>No evidence of large vessel invasion nor extra-hepatic spread.</li>
                  <li>It requires lifelong immunosuppression, is expensive, and not widely available.</li>
                </ul>
                
    
                <h4>Local Ablation</h4>
                <ul>
                  <li>For non-resectable tumors.</li>
                  <li>For patients not eligible for liver transplantation.</li>
                  <li>Percutaneous Alcohol / Ethanol injection.</li>
                  <li>Radiofrequency ablation.</li>
                  <li>Transarterial chemo-embolization (TACE).</li>
                  <li>Temporary measures only.</li>
                </ul>
    
                <h4>Percutaneous Ethanol Injection (PEI)</h4>
                <ul>
                  <li>Minimally invasive percutaneous treatment modality reserved for early HCC not eligible for hepatic resection or transplantation.</li>
                  <li>Procedure consists of injection of absolute alcohol directly into tumor nodules under US or CT guidance. Two to 12 ml of alcohol is injected twice/week on an outpatient basis for 2-15 sessions.</li>
                  <li>The best survival rates for PEI are obtained for tumors <strong>&lt; 3cm</strong> and <strong>&lt; 3 lesions</strong>.</li>
                  <li>Other less utilized agents for injection are acetic acid and hot saline.</li>
                </ul>
                
                            <!-- image here -->
                            <div class="image-container">
                              <img src="../figures/liver-neoplasms (1).gif" alt="" onclick="openModal(this)">
                              <div class="caption">Ethanol Injection USS</div>
                            </div>
                            
                            <div id="myModal" class="modal">
                              <span class="close" onclick="closeModal()">&times;</span>
                              <img class="modal-content" id="modalImage">
                              <div id="caption" class="caption">Ethanol Injection USS</div>
                            </div>
    
    
                            <h4>Radiofrequency Ablation (RFA)</h4>
                            <ul>
                              <li>RFA is the preferred ablative treatment for tumors <strong>3-5 cm</strong> in diameter.</li>
                              <li>It is superior to PEI, requires fewer sessions, has lower local recurrence, and longer overall as well as disease-free survival.</li>
                              <li>Indications include:
                                <ol type="a">
                                  <li>Very early stage HCC not amenable to resection.</li>
                                  <li>Early stage HCC not suitable for liver transplantation.</li>
                                  <li>Patients with waiting times &gt; 3 months.</li>
                                </ol>
                              </li>
                            </ul>
                       
                                        <!-- image here -->
                <div class="image-container">
                  <img src="../figures/liver-neoplasms (1).jpg" alt="" onclick="openModal(this)">
                  <div class="caption">Radiofrequency Ablation</div>
                </div>
                
                <div id="myModal" class="modal">
                  <span class="close" onclick="closeModal()">&times;</span>
                  <img class="modal-content" id="modalImage">
                  <div id="caption" class="caption">Radiofrequency Ablation</div>
                </div>
    
    
                <h4>Chemo-embolization</h4>
                <ul>
                  <li>Inject chemotherapeutic agent selectively in hepatic artery.</li>
                  <li>Then inject an embolic agent.</li>
                  <li>Embolization may be done alone (transarterial embolization) or combined with selective intra-arterial chemotherapy (TACE) using doxorubicin, mitomycin, or cisplatin and lipiodol (contrast media).</li>
                  <li>To be effective, it should be limited to patients with preserved liver function, absence of extrahepatic spread or vascular invasion, and no significant cancer-related symptoms.</li>
                  <li>The purpose of embolization is to induce ischemic tumor necrosis via acute (hepatic) arterial occlusion.</li>
                </ul>
                
                            <!-- image here -->
                            <div class="image-container">
                              <img src="../figures/liver-neoplasms (2).gif" alt="" onclick="openModal(this)">
                              <div class="caption">Chemo-embolization</div>
                            </div>
                            
                            <div id="myModal" class="modal">
                              <span class="close" onclick="closeModal()">&times;</span>
                              <img class="modal-content" id="modalImage">
                              <div id="caption" class="caption">Chemo-embolization</div>
                            </div>
    
              <h4>Systemic Chemotherapy</h4>
              <ul>
                <li>Sorafenib, an oral multikinase inhibitor, is recommended in patients with advanced HCC.</li>
                <li>Sorafenib is given at a dose of <strong>400mg PO twice daily</strong>.</li>
                <li>Improved survival of <strong>11 months</strong> has been demonstrated with sorafenib.</li>
                <li>Combination with doxorubicin IV <strong>60mg/m<sup>2</sup></strong> adds an extra <strong>3 months</strong> to the survival.</li>
                <li>Erlotinib, an inhibitor of endothelial growth factor receptor signaling, has also shown promising results.</li>
              </ul>
    
      
              </div>
            </section>
 
            </div>
          </section>

          <section id='heading-4-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-2'>Fibrolamellar Carcinoma</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>Presents in young patients (5-35 years of age).</li>
                <li>Not related to cirrhosis.</li>
                <li>AFP is normal.</li>
                <li>CT shows typical stellate scar with radial septa showing persistent enhancement.</li>
              </ul>
              

            </div>
          </section>

          <section id='heading-4-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-4-3'>Secondaries or Metastases to the Liver</a>
              </h3>
            </header>
            <div class='body'>
              <ul>
                <li>The most common site for blood-borne metastases.</li>
                <li>Common primaries: colon, breast, lung, stomach, pancreas, and melanoma.</li>
                <li>Mild cholestatic picture (ALP, LDH) with preserved liver function.</li>
                <li>Diagnosis: imaging or FNAC.</li>
                <li>Treatment depends on the primary cancer.</li>
                <li>In some cases, resection or chemo-embolization is possible.</li>
              </ul>
              

            </div>
          </section>



          
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Screening/Surveillance</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>Liver cirrhosis of any cause
              <ul>
                <li>Especially those who are HBeAg positive or have serum HBV DNA levels &ge; 2,000 IU/ml.</li>
                <li>Africans above 20 years of age.</li>
                <li>Asian males &ge; 40 years.</li>
                <li>Asian females &ge; 50 years.</li>
              </ul>
            </li>
            <li>HBsAg positive patients.</li>
            <li>Individuals with positive antibodies to HCV or increased serum HCV RNA.</li>
            <li>Positive family history of HCC.</li>
            <li>Significant alcohol consumption.</li>
            <li>Genetic hemochromatosis.</li>
            <li>Primary biliary cirrhosis.</li>
            <li>Elevated serum alpha fetoprotein (&gt; 20ng/ml).</li>
          </ul>
          
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Conclusion</a>
          </h2>
        </header>
        <div class='body'>
          <ul>
            <li>HCC still carries a dismal prognosis especially when it has become symptomatic.</li>
            <li>Current emphasis, therefore, is on diagnosis during the early asymptomatic stage by regular screening of high-risk individuals.</li>
            <li>Universally accepted screening tools are serum alpha-fetoprotein & Abd. USS or CT Scan or MRI.</li>
            <li>Any lesion detected during screening is confirmed by triple-phase helical CT or contrast-enhanced MRI or by targeted biopsy.</li>
          </ul>
          
        </div>
      </section>







      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
